Drug Sponsors' Regulatory Experience Was Mixed During PDUFA IV, According to Tufts Center for the Study of Drug Development
May 09, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 9, 2012) - Drug sponsors experienced a mixed regulatory burden under the FDA Amendments Act, which was also the fourth iteration of the Prescription Drug User Fee Act...
Drug Companies Are Looking to Shorten Time to Early Clinical Development, According to Tufts Center for the Study of Drug Development
April 26, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Apr 26, 2012) - Drug companies looking to increase the efficiency and productivity of their R&D pipelines are turning to a host of techniques and approaches aimed at...
Drugs to Treat CNS Diseases Take 35% Longer to Develop Than Other Drugs, According to Tufts Center for the Study of Drug Development
March 06, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Mar 6, 2012) - Drugs developed to treat central nervous system (CNS) diseases take 35% longer to complete clinical trials and receive regulatory approval compared to other...
Drug Company Executives Are Expanding Their Use of Strategic Partnerships, According to Tufts Center for the Study of Drug Development
January 26, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 26, 2012) - Pharmaceutical and biopharmaceutical companies, under pressure to increase R&D productivity, are expanding their use of strategic partnerships to bring...
Tufts Center for the Study of Drug Development Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates
January 17, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 17, 2012) - The Tufts Center for the Study of Drug Development today announced that it has established the first global benchmark for clinical research associate (CRA)...
Drug Companies Are Taking Steps to Improve R&D Productivity, According to Tufts Center for the Study of Drug Development
January 05, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 5, 2012) - Although drug companies are pursuing innovative approaches to increase the pace and reduce the cost of drug development, the greatest advances will come...
Number of Monoclonal Antibody Products in Development Continues to Increase, According to Tufts Center for the Study of Drug Development
November 08, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Nov 8, 2011) - Developers are steadily increasing the number of monoclonal antibody products -- known as mAbs -- for which they are initiating clinical studies, extending...
Drug Companies Are Using Innovative Partnerships to Spur Development, According to Tufts Center for the Study of Drug Development
October 06, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Oct 6, 2011) - Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative...
Majority of Clinical Trial Protocols Are Amended, but One-Third of Those Changes Are Avoidable, According to Tufts Center for the Study of Drug Development
September 13, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Sep 13, 2011) - Nearly 60 percent of all protocols used in clinical trials for new drugs are amended during the trial. Moreover, one-third of those changes could have been...
Growing Regulatory Requirements Worldwide Challenge Drug Developers, According to Tufts Center for the Study of Drug Development
August 09, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Aug 9, 2011) - As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory...